ストックスクリーナーアプリを入手
14.17
1.72%
0.24
アフターアワーズ：
13.90
-0.27
-1.91%
前日終値:
$13.93
開ける：
$14.09
24時間の取引高:
1.36M
Relative Volume:
0.79
時価総額：
$1.24B
収益：
-
当期純損益:
$-162.45M
株価収益率:
-7.5995
EPS:
-1.8646
ネットキャッシュフロー:
$-146.72M
1週間 パフォーマンス:
-2.71%
1か月 パフォーマンス:
-41.20%
6か月 パフォーマンス:
+73.02%
1年 パフォーマンス:
+238.19%
1日の値動き範囲:
$13.98
$14.38
1週間の範囲:
$13.11
$15.05
52週間の値動き範囲:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
名前
Olema Pharmaceuticals Inc
セクター
電話
(415) 651-3316
住所
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
14.17 | 1.21B | 0 | -162.45M | -146.72M | -1.8646 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 再開されました | Jefferies | Buy |
| 2026-02-11 | 開始されました | Stifel | Buy |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-10-08 | 開始されました | Guggenheim | Buy |
| 2025-08-12 | 繰り返されました | Citigroup | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2024-01-30 | 開始されました | Citigroup | Buy |
| 2023-07-21 | 開始されました | Oppenheimer | Outperform |
| 2023-05-05 | 開始されました | CapitalOne | Overweight |
| 2023-02-22 | 開始されました | Credit Suisse | Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 開始されました | H.C. Wainwright | Neutral |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2020-12-14 | 開始されました | Canaccord Genuity | Buy |
| 2020-12-14 | 開始されました | Cowen | Outperform |
| 2020-12-14 | 開始されました | JP Morgan | Overweight |
| 2020-12-14 | 開始されました | Jefferies | Buy |
すべてを表示
Olema Pharmaceuticals Inc (OLMA) 最新ニュース
Aug PostEarnings: What are analysts price targets for Olema Pharmaceuticals IncWeekly Stock Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Oppenheimer maintains Olema Pharmaceuticals (OLMA) outperform recommendation - MSN
Jim Cramer on Olema Pharmaceuticals: "Too risky for me" - MSN
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” - Insider Monkey
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility - Yahoo Finance
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? - AOL.com
Invus entities disclose 4.5% stake in Olema (OLMA) on Schedule 13G - Stock Titan
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) - GuruFocus
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Jefferies Financial Group Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Jefferies initiates Olema Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital reiterates a buy on Olema Pharmaceuticals (OLMA) - MSN
JP Morgan Raises Price Target for Olema Pharmaceuticals (OLMA) | - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead - Bitget
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Olema Pharmaceuticals (OLMA) Receives Updated Price Target by Go - GuruFocus
The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - MarketBeat
OLMA Stock Price, Quote & Chart | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Ratin - GuruFocus
Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Bitget
Lab study: Olema drug duo hits cancer growth and spread genes - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Rating | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $38.00 by Analysts at Guggenheim - MarketBeat
Guggenheim lowers Olema Pharmaceuticals price target on trial timing By Investing.com - Investing.com Canada
Breakout Zone: Should I invest in Olema Pharmaceuticals Inc before earningsWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Decoding Olema Pharmaceuticals inc (OLMA): A Strategic SWOT Insi - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat - MEXC
Short Covering: Does Olema Pharmaceuticals Inc have pricing powerVolume Spike & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch - The Motley Fool
Biotech shares surge almost 300% as $68.7 million investment backs breast cancer treatment aiming for 2027 debut - Bitget
Olema Oncology Reports 2025 Financial Results and Advances Palazestrant in Phase 3 Breast Cancer Trials - Minichart
Shane W. Kovacs sells 241,999 OLMA shares (NASDAQ: OLMA) for $3.25M - Stock Titan
Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise - MEXC
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
Olema Pharmaceuticals 2025 Annual Report: Pipeline Progress, Risk Factors, and Breast Cancer Therapy Insights - Minichart
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 8.5% on Earnings Beat - MarketBeat
Olema Pharmaceuticals delivers Q4 and full-year 2025 financial results and updates on milestones - Traders Union
Olema Pharmaceuticals (OLMA) Reports Q4 Earnings Beat - GuruFocus
Olema Oncology (OLMA) Advances Key Cancer Therapies in 2025 - GuruFocus
Olema Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Olema Pharmaceuticals Inc (OLMA) announced that patient recruitment for the Phase 1 clinical study of its candidate drug OP-3136 is underway. - Bitget
854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Olema Oncology reports Q4 EPS (50c), consensus (53c) - TipRanks
Olema Pharmaceuticals Inc (OLMA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):